Literature DB >> 20162673

Deregulation of the cell cycle by breast tumor kinase (Brk).

Edward Chan1, Anjaruwee S Nimnual.   

Abstract

Brk is a cytoplasmic nonreceptor tyrosine kinase that is overexpressed in breast tumors but undetectable in normal or benign mammary tissues. Brk promotes proliferation of human mammary epithelial cells and tumor growth in a mouse model, but the role of Brk in cell cycle regulation is not known. In this study, we describe the mechanism of Brk-induced deregulation of the cell cycle. We provide evidence that Brk antagonizes the transcriptional activity of the transcription factor FoxO family of proteins by inhibiting its nuclear localization. As a result, the cell cycle inhibitor p27, a FoxO target gene, is down-regulated. This event is accompanied by G1/S cell cycle progression of quiescent cells. As p27 is a key regulator of the G1/S cell cycle checkpoint, these data suggest that perturbation of p27 expression induced by Brk causes S phase entrance. Deregulation of the cell cycle is a key event in neoplasia, and thus, the mechanism presented here likely contributes to breast cancer development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20162673     DOI: 10.1002/ijc.25263

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Authors:  Haroon A Hussain; Amanda J Harvey
Journal:  World J Clin Oncol       Date:  2014-08-10

2.  The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin.

Authors:  Patrick M Brauer; Yu Zheng; Mark D Evans; Carmen Dominguez-Brauer; Donna M Peehl; Angela L Tyner
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

3.  Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.

Authors:  Natalie Falkenberg; Nataša Anastasov; Ines Höfig; Ksenia Bashkueva; Katrin Lindner; Heinz Höfler; Michael Rosemann; Michaela Aubele
Journal:  Mol Oncol       Date:  2014-09-06       Impact factor: 6.603

4.  Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4.

Authors:  Priyank Patel; Benedikt Asbach; Elina Shteyn; Cindy Gomez; Alexander Coltoff; Sadia Bhuyan; Angela L Tyner; Ralf Wagner; Stacy W Blain
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 5.069

Review 5.  Putting the BRK on breast cancer: From molecular target to therapeutics.

Authors:  Hui Li Ang; Yi Yuan; Xianning Lai; Tuan Zea Tan; Lingzhi Wang; Benjamin BoJun Huang; Vijay Pandey; Ruby Yun-Ju Huang; Peter E Lobie; Boon Cher Goh; Gautam Sethi; Celestial T Yap; Ching Wan Chan; Soo Chin Lee; Alan Prem Kumar
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

6.  ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1.

Authors:  Zhenchong Xiong; Liping Ye; He Zhenyu; Fengyan Li; Yahui Xiong; Chuyong Lin; Xianqiu Wu; Guangzheng Deng; Wei Shi; Libing Song; Zhongyu Yuan; Xi Wang
Journal:  Mol Oncol       Date:  2018-04-18       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.